Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL study
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL study
Authors
Keywords
-
Journal
ANNALS OF HEMATOLOGY
Volume 101, Issue 10, Pages 2169-2177
Publisher
Springer Science and Business Media LLC
Online
2022-08-24
DOI
10.1007/s00277-022-04948-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sutimlimab in Cold Agglutinin Disease
- (2021) Alexander Röth et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of Complement C1s By Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Efficacy and Safety Results from the Randomized, Placebo-Controlled Phase 3 CADENZA Study
- (2021) Alexander Roeth et al. BLOOD
- Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting
- (2019) Ulrich Jäger et al. BLOOD REVIEWS
- A Randomized, First-in-Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway
- (2018) Johann Bartko et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Assessing the reliability of the short form 12 (SF-12) health survey in adults with mental health conditions: a report from the wellness incentive and navigation (WIN) study
- (2018) Tianyao Huo et al. Health and Quality of Life Outcomes
- Complement Activation and Inhibition in Autoimmune Hemolytic Anemia: Focus on Cold Agglutinin Disease
- (2018) Sigbjørn Berentsen SEMINARS IN HEMATOLOGY
- Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial
- (2018) Ulrich Jäger et al. BLOOD
- Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS
- (2015) R. Cofiell et al. BLOOD
- Qualitative and quantitative validation of the FACIT-fatigue scale in iron deficiency anemia
- (2015) Sarah Acaster et al. Health and Quality of Life Outcomes
- Cold agglutinin disease
- (2013) P. L. Swiecicki et al. BLOOD
- C1-inhibitor efficiently inhibitsEscherichia coli-induced tissue factor mRNA up-regulation, monocyte tissue factor expression and coagulation activation in human whole blood
- (2013) A. Landsem et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation
- (2012) Ilene C. Weitz et al. THROMBOSIS RESEARCH
- High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease
- (2010) S. Berentsen et al. BLOOD
- Evaluation of the meaningfulness of health-related quality of life improvements as assessed by the SF-36 and the EQ-5D VAS in patients with active Crohn’s disease
- (2009) G. COTEUR et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Association of fatigue and psychological distress with quality of life in patients with a previous venous thromboembolic event
- (2009) Paul Lukas et al. THROMBOSIS AND HAEMOSTASIS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started